MGH researcher Gary Ruvkun named a co-recipient of the Lasker Award

September 13, 2008

Massachusetts General Hospital (MGH) and Harvard Medical School investigator Gary Ruvkun, PhD, is one of three co-recipients of the 2008 Lasker Award for Basic Medical Research. Presented by the Albert and Mary Lasker Foundation, the Lasker Awards are often considered the American version of the Nobel Prize, and many Lasker recipients have gone on to win the Nobel. The award will be presented in New York on Friday, Sept. 26.

Ruvkun and his co-recipients - Victor Ambros, PhD, of the University of Massachusetts Medical School and David Baulcombe, PhD, FRS, University of Cambridge in the U.K. - are being honored for discovering that tiny molecules of RNA can control the activity of critical genes in animals and plants. Instead of being translated into proteins as messenger RNAs are, single-stranded microRNAs bind to regulatory segments of their target genes' RNA and block gene expression. Current knowledge suggests that microRNAs may control one third of human protein-coding genes.

In the early 1980s Ruvkun and Ambros were both fellows in the Massachusetts Institute of Technology laboratory of Robert Horvitz, PhD, investigating genes that control development in the C. elegans roundworm. They worked together to isolate a gene called lin-14 that operates in concert with a gene called lin-4 to regulate the worms' transition through key developmental stages.

As the two researchers established their own laboratories - Ruvkun in the MGH Department of Molecular Biology and Ambros at Harvard - they continued collaborating to uncover how the two regulatory genes interacted and made some surprising discoveries. Lin-4 did not block the activity of lin-14 through the protein it coded for but in a manner never seen before - by direct interaction between the two genes' RNA strands. These critical RNA molecules also appeared to be extremely small, around 20 nucleotides long. In the meantime Baulcombe was pursuing similar research in plants. His discovery that plant genes could be silenced by the action of tiny RNAs - similar to the worm sequences studied by Ruvkun and Ambros - implied that the same mechanism operated in plants and animals.

In 2000 Ruvkun's team discovered let-7, another tiny regulatory RNA that shuts down its target gene the same way that lin-4 silences lin-14. They also found that the let-7 RNA sequence had been snipped out of a larger RNA molecule that folds back on itself in a hairpin shape. Later that year Ruvkun published evidence that animals from fish to flies to humans have their own versions of let-7, implying that the mechanism is universal to all but the most primitive animal species.

In 2001 Ruvkun collaborated with Craig Mello, PhD, of UMass and Andrew Fire, PhD, then at the Carnegie Institution, to show that the microRNAs of both lin-4 and let-7 are released from their precursor hairpin RNA molecules by the enzyme Dicer, which is also critical to the RNA interference process that Mello and Fire had discovered and for which they received the 2006 Nobel Prize.

It now appears that the human genome contains between 500 and 1,000 microRNAs involved in a broad range of normal and disease-related activities. Researchers have just begun exploring their potential for the diagnosis, prognosis and treatment of disorders. In addition to continuing investigation of RNA's role in controlling gene expression, Ruvkun's team studies other mechanisms involved in the development, metabolism and longevity of C. elegans, including genes involved in the regulation and storage of fat.

Ruvkun is a professor of Genetics at Harvard Medical School and an investigator at the MGH Center for Computational and Integrative Biology. He holds a bachelor's degree in Biophysics from the University of California at Berkeley and a PhD in Biophysics from Harvard University. Among the many other awards he has received - some shared with Ambros and Baulcombe - are the Franklin Medal, the Gairdner International Award and the 2008 Warren Triennial Prize from MGH. He is a member of the National Academy of Sciences.
-end-
Massachusetts General Hospital (www.massgeneral.org), established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $500 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine.

Massachusetts General Hospital

Related RNA Articles from Brightsurf:

A new RNA catalyst from the lab
On the track of evolution: a catalytically active RNA molecule that specifically attaches methyl groups to other RNAs - a research group from the University of Würzburg reports on this new discovery in Nature.

Small RNA as a central player in infections
The most important pathogenicity factors of the gastric pathogen Helicobacter pylori are centrally regulated by a small RNA molecule, NikS.

RNA as a future cure for hereditary diseases
ETH Zurich scientists have developed an RNA molecule that can be used in bone marrow cells to correct genetic errors that affect protein production.

Bringing RNA into genomics
By studying RNA-binding proteins, a research consortium known as ENCODE (Encyclopedia of DNA Elements) has identified genomic sites that appear to code for RNA molecules that influence gene expression.

RNA key in helping stem cells know what to become
If every cell has the same genetic blueprint, why does an eye cell look and act so differently than a brain cell or skin cell?

RNA structures by the thousands
Researchers from Bochum and Münster have developed a new method to determine the structures of all RNA molecules in a bacterial cell at once.

New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus
Researchers in the lab of Neville Sanjana, PhD, at the New York Genome Center and New York University have developed a new kind of CRISPR screen technology to target RNA.

Discovery of entirely new class of RNA caps in bacteria
The group of Dr. Hana Cahová of the Institute of Organic Chemistry and Biochemistry of the CAS, in collaboration with scientists from the Institute of Microbiology of the CAS, has discovered an entirely new class of dinucleoside polyphosphate 5'RNA caps in bacteria and described the function of alarmones and their mechanism of function.

New RNA mapping technique shows how RNA interacts with chromatin in the genome
A group led by scientists from the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have developed a new method, RADICL-seq, which allows scientists to better understand how RNA interacts with the genome through chromatin--the structure in which the genome is organized.

Characterising RNA alterations in cancer
The largest and most comprehensive catalogue of cancer-specific RNA alterations reveals new insights into the cancer genome.

Read More: RNA News and RNA Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.